No black box warning on record for Hympavzi

As of the latest FDA labeling reviewed, Hympavzi (MARSTACIMAB-HNCQ) does not carry a black box warning. Standard warnings and precautions still apply — see the full Hympavzi medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS • Thromboembolic Events: Thromboembolic events may occur. Interrupt HYMPAVZI prophylaxis if symptoms occur. ( 5.1 ) • Hypersensitivity: Hypersensitivity reactions may occur. In the event of a severe allergic reaction, discontinue HYMPAVZI. ( 5.2 ) • Embryofetal Toxicity: May cause fetal harm. Advise females of reproductive potential of the potential risk to the fetus and

No black box warning on record for Hympavzi

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS • Thromboembolic Events: Thromboembolic events may occur. Interrupt HYMPAVZI prophylaxis if symptoms occur. ( 5.1 ) • Hypersensitivity: Hypersensitivity reactions may occur. In the event of a severe allergic reaction, discontinue HYMPAVZI. ( 5.2 ) • Embryofetal Toxicity: May cause fetal harm. Advise females of reproductive potential of the potential risk to the fetus and

Hympavzi Black Box Warning

No black box warning on record for Hympavzi

Other warnings & precautions

Hympavzi Black Box Warning

No black box warning on record for Hympavzi

Other warnings & precautions